TipRanks
Go Ultimate55% OFF

Ipsen (IPNN) Stock Price & Analysis

IPNN Stock Chart & Stats

MX$3,384.27MX$0.00(0.00%)
At close:
MXN 2,000MXN 2,500MXN 3,00026 Aug16 Apr25 Jul13 Nov9 Jul
Day’s Range
MXN 3,384.27 - MXN 3,384.27
52-Week Range
MXN 2,617.44 - MXN 3,384.27
Previous Close
MXN 3,384.27
Volume
0
Average Volume (3M)
0
Market Cap
MXN 274.40B
Enterprise Value
MXN 12.99B
Total Cash (Recent Filing)
MXN 1.97B
Total Debt (Recent Filing)
MXN 963.20M
Price to Earnings (P/E)
25.4
Beta
0.11
Next Earnings
Feb 11, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
0.87%

Bulls Say, Bears Say

Bulls Say

Sustained Revenue Growth

Steady multi-year revenue expansion indicates sustained demand for Ipsen’s specialty medicines and growing commercial reach. Continued top-line growth can support investment in clinical development, lifecycle management, and commercial capabilities across oncology, rare diseases, and neuroscience.

Healthy Profitability

Ipsen remains meaningfully profitable despite margin pressure, with a 30% EBITDA margin providing operating capacity to fund innovation and commercialization. This profitability supports resilience across its specialty portfolio and gives management flexibility to pursue durable growth opportunities.

Conservative Leverage

Low leverage and a growing equity base provide Ipsen with a relatively resilient financial structure. This reduces balance-sheet strain, preserves borrowing capacity for strategic investment, and improves the company’s ability to absorb operating volatility while continuing to develop specialty medicines.

Bears Say

Margin Compression

The substantial decline in net margin shows that revenue growth has not translated into stable profitability at prior levels. If higher costs or unfavorable product mix persist, Ipsen may have less earnings available for research, commercial investment, and shareholder returns.

Sharp Debt Increase

The sharp year-over-year increase in total debt weakens an otherwise conservative capital structure and raises the importance of future deleveraging or sustained cash generation. Higher obligations could constrain capital allocation if operating performance or cash conversion becomes less consistent.

Cash-Flow Volatility

The strong 2025 cash-flow rebound is encouraging, but the prior weakness and inconsistent relationship between operating cash flow and profitability indicate execution or working-capital variability. Such volatility can complicate funding of research, acquisitions, and other long-term priorities.

Ipsen News

IPNN FAQ

What was Ipsen’s price range in the past 12 months?
Ipsen lowest stock price was Mex$2617.44 and its highest was Mex$3384.27 in the past 12 months.
What is Ipsen’s market cap?
Ipsen’s market cap is Mex$274.40B.
When is Ipsen’s upcoming earnings report date?
Ipsen’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 102 days.
How were Ipsen’s earnings last quarter?
Ipsen released its earnings results on Jul 30, 2026. The company reported Mex$153.882 earnings per share for the quarter, beating the consensus estimate of Mex$132.678 by Mex$21.203.
Is Ipsen overvalued?
According to Wall Street analysts Ipsen’s price is currently Overvalued.
Does Ipsen pay dividends?
Ipsen does not currently pay dividends.
What is Ipsen’s EPS estimate?
Ipsen’s EPS estimate is 165.34.
How many shares outstanding does Ipsen have?
Ipsen has 83,814,530 shares outstanding.
What happened to Ipsen’s price movement after its last earnings report?
Ipsen reported an EPS of Mex$153.882 in its last earnings report, beating expectations of Mex$132.678. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ipsen?
Currently, no hedge funds are holding shares in MX:IPNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology